Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 22.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 03.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nal 8-K”) for the sole purpose of supplementing Item 5.02 of the Original 8-K to include additional disclosure regarding |
| 07.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 28.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 18.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 29.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ACTIVE/122789132.1 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 04.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ACTIVE/122789132.1 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 22.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. ☐ Item 5.02. Compensatory Arrangements of Certain Officers. As described under Item 5.07 of this Curr |
| 18.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on arrangements and other information required by Item 5.02 of Form 8-K. Also on July 18, 2023, as a complement to the O |
| 17.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ACTIVE/122789132.1 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 02.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n Form 8-K is incorporated by reference into this Item 5.02. Item 5.07 Submission of Matters to a Vote of Security Hol |
Stammdaten
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Unternehmen & Branche
| Name | AMARIN CORP PLC\UK |
|---|---|
| Ticker | AMRN |
| CIK | 0000897448 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | ADR |
| Marktkapitalisierung | 289,6 Mio. USD |
| Beta | 0,82 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 213,646,000 | -38,798,000 | -0.09 | 670,775,000 | 459,281,000 |
| 2025-09-30 | 10-Q | 49,670,000 | -7,738,000 | -0.02 | 659,814,000 | 458,894,000 |
| 2025-06-30 | 10-Q | 72,741,000 | -14,139,000 | -0.03 | 670,126,000 | 464,924,000 |
| 2025-03-31 | 10-Q | 42,017,000 | -15,697,000 | -0.04 | 655,677,000 | 473,687,000 |
| 2024-12-31 | 10-K | 228,614,000 | -82,183,000 | -0.20 | 685,349,000 | 486,176,000 |
| 2024-09-30 | 10-Q | 42,298,000 | -25,134,000 | -0.06 | 750,615,000 | 531,375,000 |
| 2024-06-30 | 10-Q | 67,491,000 | 1,522,000 | 0.00 | 799,855,000 | 551,879,000 |
| 2024-03-31 | 10-Q | 56,519,000 | -9,953,000 | -0.02 | 790,013,000 | 545,936,000 |
| 2023-12-31 | 10-K | 306,911,000 | -59,112,000 | -0.15 | 831,684,000 | 552,097,000 |
| 2023-09-30 | 10-Q | 66,056,000 | -19,311,000 | -0.05 | 839,031,000 | 553,148,000 |
| 2023-06-30 | 10-Q | 80,167,000 | -17,560,000 | -0.04 | 860,018,000 | 569,128,000 |
| 2023-03-31 | 10-Q | 85,975,000 | -16,460,000 | -0.04 | 860,188,000 | 584,793,000 |
| 2022-12-31 | 10-K | 369,193,000 | -105,803,000 | -0.26 | 886,179,000 | 595,333,000 |
| 2022-09-30 | 10-Q | 89,878,000 | -5,140,000 | -0.01 | 908,303,000 | 587,827,000 |
| 2022-06-30 | 10-Q | 94,440,000 | -69,956,000 | -0.18 | 973,237,000 | 580,043,000 |
| 2022-03-31 | 10-Q | 94,630,000 | -31,563,000 | -0.08 | 973,709,000 | 641,109,000 |
| 2021-12-31 | 10-K | 583,187,000 | 7,729,000 | 0.02 | 1,068,065,000 | 667,099,000 |
| 2021-09-30 | 10-Q | 142,038,000 | -13,151,000 | -0.03 | 1,035,805,000 | 642,495,000 |
| 2021-06-30 | 10-Q | 154,488,000 | 7,808,000 | 0.02 | 1,044,991,000 | 645,324,000 |
| 2021-03-31 | 10-Q | 142,170,000 | -1,626,000 | 0.00 | 990,252,000 | 634,611,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.